Citations

Clear

1526 citation(s) found for "Sun, Yu".

Olfactory decline in aging: longitudinal trajectories and associations with cognitive decline and postmortem neuropathology
Tremblay, Cécilia , Driver-Dunckley, Erika, Alasmar, Zaki , Serrano, Geidy E, Shill, Holly A. , Mehta, SH, Ho, Andrew, Fereshtehnejad, Seyed-Mohammad , Shprecher, David, Lorenzini, Ileana , Belden, Christine M. , Atri, Alireza, Adler, Charles H, Beach, Thomas G, Dadar, Mahsa, Zeighami, Yashar, Choudhury, Parichita , Driver‐Dunckley, Erika , Serrano, Geidy E. , Mehta, Shyamal H. , Ho, Andrew H, Shprecher, David , Atri, A., Adler, Charles H. , Beach, Thomas G. , Dadar, Mahsa , Zeighami, Yashar

Mayo Clinic

No container title available | April 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.27.26351817 | PMID 42094133 Get It

Abstract Importance Decline in olfactory function may be used as a predictor of cognitive decline, to enhance early detection models, improve risk stratification, and enable early intervention. Objective To assess the longitudinal association between olfactory decline, cognitive decline, and postmortem neuropathology. Design, setting and participants Retrospective longitudinal analysis with clinicopathological correlations of a prospective population-based cohort study using data from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) and its Brain and Body Donation Program. Participants included cognitively unimpaired individuals without parkinsonism that converted to mild cognitive impairment (MCI) and/or dementia or remained cognitively stable. Main Outcomes and Measures longitudinal change in olfaction, neuropsychiatric symptoms, motor function and memory, conversion to MCI/dementia, postmortem neuropathology Results Over a mean follow-up period of 7.7 ± 5.4 years, out of 922 participants who were cognitively unimpaired at the first cognitive conference, 643 remained cognitively unimpaired, 279 converted to MCI, and 82 developed dementia. Of these, 633 individuals had at least 2 olfactory tests. Converters showed reduced olfactory function (t=-12.6, p <0.0001), faster progression in neuropsychiatric symptom burden (t=3.42, p < 0.001), and faster decline in memory (t= -7.33, p <0.0001) prior to conversion while no significant differences were observed in motor scores between converters and non-converters. Using ROC analysis, olfactory decline, increased neuropsychiatric symptom burden, as well as motor and memory decline predicted conversion to MCI with a consistent accuracy of ∼ 70% up to 5 years before conversion, while UPSIT alone had an accuracy of ∼ 60%. Longitudinal decline in olfaction was associated with a higher burden of a-synuclein (t= -8.21, p <0.0005), tau tangle (t= -2.66, p < 0.01) and amyloid plaque burden (t= -2.85, p < 0.005) and a faster decline over time was associated with a higher burden of tau (t=5.66, p<0.0001). Conclusions and Relevance A reduction in olfactory identification ability is observed up to a decade prior to conversion to MCI and is associated with underlying burden of neuropathology markers, underscoring the value of incorporating olfactory testing in cognitively unimpaired individuals to identify those at-risk of future cognitive decline.
Multisite study: Predicting Lewy body disease using skin biopsy α-synuclein seed amplification assays
Janarthanam, Chelva, Hughson, Andrew G, Holzinger, David, Taylor, Keenan, Caughey, Byron, Adler, Charles H, Shill, Holly A, Mehta, SH, Driver-Dunckley, Erika, Ho, Andrew H, Shprecher, David R, Belden, Christine M. , Atri, Alireza, Zhang, Nan, Chen, Kewei, Serrano, Geidy E, Beach, T, Beach, Thomas G , Orru, Christina Doriana , Hughson, Andrew G. , Kanthasamy, Anumantha G. , Caughey, Byron W. , Heym, Roland G. , Adler, Charles H. , Shill, Holly A. , Mehta, Shyamal H. , Driver‐Dunckley, Erika , Choudhury, Parichita , Shprecher, David , Atri, A., Serrano, Geidy E. , Beach, Thomas G.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | April 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnen/nlag048 | PMID 42223057 Get It

Abstract Skin biopsies analyzed with α-synuclein seed amplification assays (SAAs) are a simple way to clinically interrogate the presence of α-synuclein aggregates. We determined the accuracy of skin biopsy SAA in predicting the clinical diagnoses of Parkinson disease (PD), PD with dementia (PDD) and dementia with Lewy bodies (DLB). Blinded SAAs were performed in 3 independent laboratories. Subjects diagnosed with PD, PDD and DLB were analyzed together as group 1, clinically unaffected subjects as group 2 and those with risk factors for LBD as group 3. Punch biopsies were taken from the posterior neck and analyzed by the 3 labs in 6 separate SAAs. Pairwise agreement between labs and assays ranged from excellent (kappa 0.82) to moderate (kappa 0.40-0.68). Sensitivity across assays ranged between 50.0% and 61.3%; specificity ranged between 68.6% and 100%. Comparisons of group 1 vs group 2 produced the greatest specificities, between 77.3% and 100%. In 17 cases that subsequently came to autopsy, 93% of SAAs were positive in those at the neocortical LBD stage but in only &lt;10% of those at lower stages. Skin biopsy α-synuclein SAA may be useful as a diagnostic and progression biomarker in Lewy body dementia clinical trials.
Data Distribution Evolution for Robust EEG Emotion Recognition with Limited Data Resource
Wang, Zhenyi , Shen, Li, Niu, Shuteng , Doretto, Gianfranco , Adjeroh, Donald , Tao, Cui, Tao, Cui , Shen, Li , Tao, Cui , Niu, Shuteng , Duan, Tiehang , Shen, Li

Mayo Clinic

IEEE Transactions on Affective Computing | April 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-14

10.1109/taffc.2026.3684827 Get It

Integrating oncology advanced practice providers and clinical pharmacists into clinical cancer research
Braun‐Inglis, Christa , Myers, Jamie, O’Brien, Bridget, Kottschade, Lisa A. , Flannery, Marie , DeTroye, Alisha , Elko, Theresa A. , Leatherwood, Amy, Mader, Alyssa, Wong, Siu Fun, Foust, Melyssa , Benson, Al B., Primeaux, Brian , Demirhan, Kimberly , Statler, Tiffany, Vogel, Wendy , Kottschade, Lisa, Braun-Inglis, Christa M , Myers, Jamie , O'Brien, Bridget, Leatherwood, Amy Eiko , Bakitas, Marie , Benson, Al B. , Berenberg, Jeffrey L. , Rosenzweig, Margaret Quinn , Statler, Tiffany M. , Sun, Virginia Chih-Yi

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag125 | PMID 42015388 Get It

Abstract Oncology Advanced Practice Providers (APPs), including Advanced Practice Registered Nurses, Physician Assistants, and Clinical Pharmacists (CPs), play a vital role in delivering high-quality, patient-centered cancer care across the United States. Despite their widespread presence in oncology practices, APPs remain underutilized in cancer clinical research, representing a missed opportunity to expand trial access and improve patient outcomes. Clinical trials are essential to advancing oncology care, yet participation remains critically low among adult patients. Given Oncology APPs’ and CPs’ central role in cancer care delivery, their meaningful engagement in oncology clinical trial research is imperative as the standard of oncology care. This position article, with contributions from 5 professional societies, presents solutions and resources to barriers limiting APPs’ and CPs’ involvement in cancer clinical research, including gaps in education, role expectations, limited protected time, restrictive policies, insufficient financial support, and underrecognition of contributions. Integrating APPs and CPs more fully into the clinical research enterprise is essential to improving trial access, patient outcomes, closing equity gaps, and accelerating innovation in oncology care.
Imaging solute transportation along the posterior lymphatic pathway in the ocular glymphatic system in healthy human participants
Wen, Xuehua , Sun, Yuanqi, Li, Yinghao, Paez, Adrian , Varghese, Jacob , Knutsson, Linda, Zijl, Peter C.M. Van, Graley, Christina R, Bakker, Arnold, Ward, Bryan K., Kashani, Amir H. , Sun, Yuanqi , Zhou, Xinyi Yedda , Li, Yinghao , Varghese, Jacob, Pillai, Jay J. , Knutsson, Linda , Zijl, Peter C.M. van , Leigh, Richard J. , Kamson, David , Saidha, Shiv , Bakker, Arnold , Ward, Bryan Kevin

Mayo Clinic

No container title available | April 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.03.26349283 | PMID 42006786 Get It

Abstract Background Recently, a posterior pathway for fluid drainage from the retina to the meningeal lymphatics in the optic nerve (ON) sheath was identified in rodents using intravitreal imaging tracers directly injected into the ocular-globe. Fluid and solute clearance along this pathway may be associated with many diseases. However, intravitreal tracers are rarely used in clinical imaging. As intravenous Gadolinium-based-contrast-agent (GBCA) can enter the globe via the blood-ocular-barriers, it may provide an alternative approach to image this pathway. Purpose To establish a clinically feasible intravenous GBCA-based MRI approach for tracking fluid and solute transport along the posterior lymphatic pathway in the ocular glymphatic system. Materials&Methods This prospective study was conducted from March 2021 to September 2022 in healthy participants. Dynamic-susceptibility-contrast-in-the-CSF (cDSC) MRI was performed before, immediately and 4 hours after intravenous-GBCA administration to track GBCA distribution in aqueous humor (AH) and cerebrospinal fluid (CSF) in regions-of-interest (ROIs) in the globe (anterior-cavity, vitreous-body), in the intraorbital and extraorbital ON, and in the intracranial CSF space proximal to the ON (chiasmatic-cistern, interpeduncular-cistern). Kruskal–Wallis tests with post-hoc Dunn’s tests were used for group comparisons. Results Sixteen healthy participants (mean age±SD: 51±21 years, 5 men) were recruited. Intravenous-GBCA enhancement was observed in all ROIs immediately after injection. At 4-hour-post-GBCA, the vitreous body showed a trend of smaller enhancement area (55±11% versus 49±11%, P =.14) and lower GBCA-concentration (0.044±0.014 versus 0.028±0.010 mmol/L, P =.07) compared to immediate-post-GBCA. The intraorbital ON showed more widespread enhancement (39±5% versus 59±6%, P =.01) and significantly higher GBCA-concentration (0.023±0.009 versus 0.059±0.015 mmol/L, P <.001) at 4-hour-post-GBCA. Conclusion Dynamic fluid and solute transportation along the posterior lymphatic pathway in the ocular glymphatic system in healthy participants was measured by tracking intravenous-GBCAs entering the globe via the blood-ocular-barriers using cDSC-MRI. Summary Statement Dynamic fluid and solute transportation along the posterior lymphatic pathway in the ocular glymphatic system in healthy participants was measured by tracking intravenous-Gadolinium-based-contrast-agents entering ocular-globe via blood-ocular-barriers using dynamic-susceptibility-contrast-in-the-CSF (cDSC)-MRI. Key Results In this prospective study of sixteen participants, Gadolinium-based-contrast-agent (GBCA)-induced signal changes were detected in the aqueous-humor and cerebrospinal fluid immediately following intravenous administration using dynamic-susceptibility-contrast-in-the-CSF (cDSC)-MRI. At 4-hour-post-GBCA, the vitreous-body showed a trend of smaller enhancement area (55±11% versus 49±11%, P =.14) and lower GBCA-concentration (0.044±0.014 versus 0.028±0.010 mmol/L, P =.07) compared to immediate-post-GBCA. The intraorbital-optic-nerve showed more widespread enhancement (39±5% versus 59±6%, P =.01) and higher GBCA-concentration (0.023±0.009 versus 0.059±0.015 mmol/L, P <.001) at 4-hour-post-GBCA.
Comparison of neuropsychological side effects between contemporary radiofrequency ablative neurosurgery for psychiatric disorders and conventional neurosurgical procedures: systematic review and meta-analysis
Vilela-Filho, Osvaldo , Bannach, Matheus A., Lino-Filho, Adriano M. , Nuttin, Bart , Hariz, Marwan , Schulder, Michael , Greenberg, Benjamin David, Cosgrove, Rees, Oliveira-Souza, Ricardo de, Horn, Andreas, Sheth, Sameer A, Kubu, Cynthia S. , Salem, Sherif, Zaccariotti, Alice Jardim, Tavares, Naraiana O, Damasceno, Benito Pereira, Lozano, Andres M, Visser-Vandewalle, Veerle, Kühn, JP, Slavin, K. V., Lopes, A. Dwight, Vattimo, Edoardo FQ, Coyne, Terry, Akram, Harith, Toda, Hiroki , Halpern, Casey H. , Coenen, Volker A., Gorgulho, Alessandra, Andrade, Pablo, Wu, Hemmings , Sun, Bomin, Belmonte-De-Abreu, Paulo, Cosyns, Paul, McLaughlin, Nicole , Giordano, Prof. J., Berk, Michael, Chabardes, Stephan, Abbadi, Najia E, Salles, Antonio Afonso Ferreira De, Enslin, Nico, Sousa, Marcelo Basso de, Oliveira, José Oswaldo, Labruna, Rodrigo, Reis, Antonio Marcos dos , Jiménez-Ponce, Fiacro , Ferragut, Maria Alice, Régis, Jean, Lipsman, Nir , Rezai, Ali R. , Schuurman, Rick, Martínez-Álvarez, Roberto, Broggi, Giovanni, Huys, Daniel, Bervoets, Chris , Oliveira, P. A., Ragazzo, Paulo C., Lazaro-Munoz, Gabriel, Polosan, Mircea , Naesström, Matilda, Ribeiro, Telma MC, Lee, Kendall H, Hodaie, Mojgan , Sitnikov, Andrey, Yilmaz, Atilla, Almahariq, F., Rios, Adriana L Lopez, Gonçalves-Ferreira, António, Lozano, Andrés M. , Huys, Daniel , Enslin, Nico , Nuttin, Bart , Hariz, Marwan , Sheth, Sameer A , Damasceno, Benito Pereira , Kuhn, Jens , Slavin, Konstantin V. , Doshi, Paresh , Toda, Hiroki , Andrade, Pablo , Zrinzo, Ludvic , Chabardes, Stephan , Chang, Jin Woo , Polosan, Mircea , Hodaie, Mojgan , Almahariq, Fadi , Nico Enslin, Johannes M , Hamani, Clement , Greenberg, Benjamin D. , Oliveira‐Souza, Ricardo de , Sheth, Sameer A. , Zaccariotti, Alice Jardim , Tavares, Naraiana de Oliveira , Mayberg, Helen S. , Visser-Vandewalle, Veerle E. R. M. , Falkai, Peter , Lopes, Antonio C, Vattimo, Edoardo Filippo de Queiroz , Akram, Harith , Blomstedt, Patric C. , Quevedo, João , Belmonte-de-Abreu, Paulo Silva , Alkhani, Ahmed M. , Berk, Michael , Yatham, Lakshmi N. , Abbadi, Najia El , Salles, Antonio A. F. De, Chang, Jin Woo , Régis, Jean , Torres, Cristina V. , Taira, Takaomi , Barcia, Juan Antonio , Schuurman, Rick , Dougherty, Darin Dean , Giacobbe, Peter , Lázaro‐Muñoz, Gabriel , Naesström, Matilda , Johansson, Viktoria , Schlaepfer, Thomas Eduard , Neimat, Joseph S. , Sitnikov, A., Yilmaz, Atilla, Almahariq, Fadi, Ríos, Adriana Lucia López , Gonçalves-Ferreira, António JC.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | April 7, 2026 | Volume: 97 | Issue: 6 | Pages: 532-541

10.1136/jnnp-2025-337800 | PMID 41946555 Get It

Background Psychiatric disorders are increasingly contributing to global disability. Despite advances in conservative management, the prevalence of treatment-resistant cases remains high. Meanwhile, neurosurgery for psychiatric disorders (NPD) remains underused, largely due to strict regulations and historical concerns, particularly those related to neuropsychological side effects (NPSE). Objective To address this issue, we conducted a systematic review with meta-analysis to compare NPSE associated with radiofrequency ablative NPD to those observed in neuro-oncological, neurovascular and epilepsy surgeries. Methods PubMed, Embase and LILACS databases were searched in April 2024 for articles published in English/Spanish from 1990 to 2022, following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Results A total of 48 articles with 2678 participants were included. The frequency of transient and permanent NPSE in the NPD group ranged from 0.94% to 11.50% and 0.94% to 2.03%, respectively, comparable to the other surgical groups (epilepsy: 0.31–11.70%; vascular: 0.52–22.90%; oncology: 0.94–17.60% for transient NPSE; epilepsy: 0.31–12%; vascular: 0.40–1.96% and oncology: 0.84–1.48% for permanent NPSE). Regarding permanent NPSE, arguably the most critical consideration, the NPD group showed better outcomes in memory, language and social cognition than the epilepsy group, but worse outcomes in executive and perceptual-motor functions. Compared with the vascular group, the NPD group had better executive function but worse complex attention. Finally, the NPD group had fewer permanent deficits than the oncology group in executive function, complex attention and perceptual-motor domains, although language performance was lower. Conclusions Contemporary NPD apparently carries a similar risk of NPSE as other conventional neurosurgical procedures, challenging misconceptions and this unjustified barrier to its broader use.
XACT‐guided interventional procedures: A feasibility study
Yan, Yuchen , Pandey, Prabodh Kumar , Xu, Yifei , Xiang, Shawn (Liangzhong), Sun, Leshan, Sun, Leshan , Abi‐Jaoudeh, Nadine , Wang, ‪Zhehui , Xiang, Shawn

Mayo Clinic

Medical Physics | April 6, 2026 | Volume: 53 | Issue: 4 | Pages: No page available

10.1002/mp.70401 | PMID 41937299 Get It

Abstract Background X‐ray Induced Acoustic Computed Tomography (XACT) is an emerging imaging technique that provides 3D volumetric images from a single projection by detecting X‐ray‐induced acoustic (XA) waves with ultrasound (US) transducers. Unlike MRI or CT, XACT enables real‐time 3D imaging without long acquisition times, 2D limitations, or motion artifacts from mechanical rotation. Furthermore, when integrated with conventional pulse‐echo US through time‐sequenced operation, XACT provides complementary soft‐tissue contrast, establishing it as a promising platform for dynamic interventional radiology (IR) guidance. Purpose This study aims to evaluate the feasibility of XACT as a novel imaging tool for IR, specifically for guiding needle placement and monitoring contrast agent dynamics. Methods We developed a 3D XACT imaging system equipped with a 256‐element 2D matrix array and a portable X‐ray tube to visualize needle insertion and contrast agent dynamics. To capture both needle position and soft tissue anatomy, we integrated a dual‐modality system combining XACT with pulse‐echo US using a 128‐element linear US array. Experiments were conducted on both tissue‐mimic phantoms and soft tissue samples. GPU‐accelerated algorithm has been developed for 3D XACT image reconstruction. Results The results demonstrate the 3D capabilities of XACT imaging for interventional procedures, including monitoring of needle placement and tracking of contrast agent dynamics. The imaging speed reached up to 3∼4 s per frame, constrained by the repetition rate of the X‐ray source and signal to noise ratio. The dual‐modality approach provided clear visualization of the needle's position and the surrounding soft tissue structures, achieving imaging resolution around 2 mm. Conclusions This study demonstrates that XACT imaging is feasible to be used for IR. Its 3D imaging capability with faster imaging speed would be an alternative to cone beam CT and its capability to combine US imaging will provide richer information for soft tissue
TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer
Wu, Bogang , Thant, Win , Bitman, Elena , Liu, T., Liu, Jie, Paschalis, E., Patel, B., Nawrocki, Cole , Xu, K., Nieman, Linda T, Ting, David T, Cheng, Yang, Sun, Fengfei, Thimmiah, Nayana , Sun, S., Abelman, R. O., Bossuyt, Veerle , Isakoff, Steven J. , Spring, L., Bardia, Aditya, Ellisen, Leif W. , Wu, Bogang , de Gois Macedo, Bruna, Paschalis, Eleftherios I. , Patel, Bidish K. , Nieman, Linda T. , Ting, David T. , Macedo, Bruna de Gois , Jiang, Kevin , Abelman, Rachel O. , Bardia, Aditya

Mayo Clinic

Journal for ImmunoTherapy of Cancer | April 3, 2026 | Volume: 14 | Issue: 4 | Pages: e012265

10.1136/jitc-2025-012265 | PMID 41932810 Get It

Background Immune exclusion inhibits antitumor immunity and response to immunotherapy, but its mechanisms remain poorly defined. In triple-negative breast cancer (TNBC), an aggressive and generally immune-rich subtype, an immune-cold microenvironment predicts poor prognosis due to a limited response to chemotherapy and immune checkpoint inhibitors. This study aimed to identify mechanisms regulating immune infiltration in TNBC. Methods We performed spatial transcriptomic analysis comparing immune-enriched versus immune-cold treatment-naïve TNBCs. Functional analyses, including loss-of-function and reconstitution experiments, were conducted to investigate the role of trophoblast cell-surface antigen 2 (TROP2), a key target of anticancer antibody drug conjugates (ADCs), in promoting TNBC progression. A humanized TROP2 syngeneic TNBC model was used to assess the effects of TROP2-targeting in combination with anti-programmed cell death protein 1 (PD-1) therapy. Additionally, data from patients treated with immune checkpoint blockade were used to test hypotheses from the preclinical findings. Results We reveal that TROP2 controls barrier-mediated immune exclusion in TNBC through claudin 7 association and tight junction regulation. TROP2 expression is inversely correlated with T-cell infiltration and predicts poor outcomes in TNBC. We demonstrate that TROP2 is sufficient to drive tumor progression in vivo in a CD8 T cell-dependent manner, while its loss deregulates expression and localization of multiple tight junction proteins, enabling T-cell infiltration. We show that TROP2 targeting via hRS7, the antibody component of the ADC sacituzumab govitecan, enhances the anti-PD-1 response and improves T-cell accessibility and effector function. Correspondingly, TROP2 expression is highly associated with lack of response to anti-PD-1 therapy in human breast cancer. Conclusions This study defines a new mechanism of barrier-mediated immune exclusion in cancer controlled by TROP2-dependent tight junctions. This mechanism drives tumor progression but can be targeted via TROP2-directed therapy to activate antitumor immunity and enhance immunotherapy response.
CLO26-083: Potential BMI-Dependent MACE Risk in Postmenopausal Breast Cancer Patients Treated With CDK4/6 Inhibitors: A Mayo Clinic Platform Study
Sun, C, Han, Yiqun, Fickel, Abigail, Liu, Li , Lees, Elizabeth , Lees, Elizabeth H.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 27, 2026 | Volume: 24 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2025.7465 | PMID 42061454 Get It

Performance Modeling of Lightweight Retrieval-Augmented Large Language Models for Low-Resource Plastic Surgery Settings
Sun, Nora Y. , Prabha, Srinivasagam, Gomez-Cabello, Cesar A., Haider, Syed Ali, Collaco, Bernardo, Pan, T. K., Wood, Nadia , Forte, Antonio Jorge, Forte, Antonio J. , Haider, Syed Ali , Collaço, Bernardo Gabriele , Sun, Nora Yanyi , Haider, Syed A , Collaco, Bernardo G , Pan, Theophilus, Wood, Nadia , Forte, Antonio Jorge , Genovese, Ariana , Prabha, Srinivasagam , Gomez-Cabello, Cesar A.

Mayo Clinic

Bioengineering | March 25, 2026 | Volume: 13 | Issue: 4 | Pages: 378

10.3390/bioengineering13040378 | PMID 42072172 Get It

Background: Large language models (LLMs) are being used by surgeons for education and reference yet concerns about hallucinations and reliability limit safe adoption. Retrieval-augmented generation (RAG) can offer a potential solution by grounding responses in a high-quality external database (e.g., medical textbooks) to enhance accuracy. However, performance tradeoffs across different RAG configurations—many of which exponentially increase computational cost—remain poorly characterized. Methods: In total, 120 lightweight, open-source RAG configurations were evaluated across 40 plastic surgery-focused question-answering tasks (20 single-hop, 20 multi-hop), spanning multiple subspecialties (4800 total evaluations). Configurations varied by base LLM (Phi-3-mini-128k-instruct vs. BioMistral-7B), embedding model, database size, chunk size, and query hop type. Performance was assessed using semantic similarity (Ragas) to physician-validated reference answers. Performance was analyzed using linear mixed-effects regression with query as a random effect and fixed and interaction effects selected via likelihood testing and AIC. Results: High performance was achievable using lightweight, open-source models. While BioMistral-7B had high mean sematic similarity under specific configurations (mean semantic similarity up to 0.786), Phi-3-mini-128k-instruct demonstrated more consistent performance across query complexity. Larger database sizes significantly improved semantic similarity, with the largest gain at intermediate sizes (e.g., size 5: +0.043, p = 0.001). Embedding choice had a strong effect, with bge-large-en-v1.5 improving performance (p = 0.0016) and Bio_ClinicalBERT markedly reducing it (p < 0.001). Multi-hop queries substantially reduced performance (p < 0.001), though this effect was attenuated for Phi-3-mini-128k-instruct via a strong model × hop-type interaction (p < 0.001). Conclusions: RAG systems for plastic surgery do not require large proprietary models, as performance depends on configuration choices and interaction effects rather than isolated components. With advancements, predictive modeling may enable resource-efficient, safe deployment of clinical RAG systems.